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Background

Pre-hospital Stroke Treatment Organization (PRESTO)
The PRE-hospital Stroke Treatment Organization (PRESTO) was formed in 2016 as an international consortium of medical practitioners involved in prehospital treatment of patients with acute stroke. PRESTO's mission is to improve stroke outcomes by supporting research and advocacy for pre-hospital stroke treatment in Mobile Stroke Units (MSUs). PRESTO will provide a platform to enhance collaborative research across the spectrum of acute stroke management in the pre-hospital setting. PRESTO will also facilitate the appropriate proliferation and distribution of MSUs by providing a forum for professional communication, resource for public education, and stimulus for government, industry, and philanthropic support. PRESTO is not-for-profit, with membership currently open to anyone involved (or hoping to become involved) in pre-hospital stroke care. PRESTO has a Steering Committee comprised of members from Europe, U.S., Canada, Australia, and other regions having a MSU in operation. PRESTO convenes satellite meetings for membership at the ISC and ESOC each year to address the PRESTO mission.
Over the next year, by-laws will be constructed providing details on not-for profit status, membership criteria, governance (including board of directors, officers and voting), meetings, committees, publication policy, and funding. The PRESTO group will also ensure involving the ''patient voice'' by inviting contributors of patient groups and emergency care organizations.
Time-to-treatment rationale
After cerebral artery occlusion, the extent of damage depends on the gradient of reduced blood flow in the respective supply area and time from onset. A complex pathophysiological cascade starts expanding, affecting brain cells over time and space. 1 Typically, a zone of irreversible cell death, the infarct core, starts to grow within minutes of stroke onset. Simultaneously, a perilesional zone-the so-called ischemic penumbra-has lost its function due to reduced blood supply leading to partially impaired energy metabolism, but still maintains its structural integrity. Per definition, this penumbral tissue consists of potentially salvageable tissue. Reperfusion of the penumbra using intravenous tissue plasminogen activator (tPA) or endovascular thrombectomy (ET) has been proven in clinical trials and transformed acute stroke therapy.
There is a close association between delay from stroke onset to treatment with both tPA and ET and irreversible tissue damage-the ''time-is-brain'' rationale. 2 Hence, timely reperfusion by reopening the occluded artery is the key to achieve better outcome. In contrast, despite promising results in animal models, neuroprotective attempts in humans have failed so far. 3 While neuroprotection without reperfusion seems unlikely to be a successful strategy, the ''freezing penumbra'' concept, based on the assumption that salvageable tissue can be preserved by blocking the ischemic cascade until the blood supply is re-established remains under investigation. [4] [5] [6] [7] However, the early induction of secondary cell death in the penumbra would also probably require starting such treatments very quickly after arterial blockage.
Approaches to time savings
Several attempts have been made to shorten time from stroke onset to starting treatment. The mean door-toneedle times of 68 min in the mainly European ''Safe Implementation of Thrombolysis in Stroke-Monitoring Study'' (SITS-Most) 8 and 79 min in the American ''Get With the Guidelines-Stroke Program'', 9 revealed a clear potential of time savings by optimizing in-hospital processes. In both registry studies, more than half the delay from stroke onset to treatment were attributed to procedures after hospital arrival. Some groups reported shortening of door-to-needle times to 20-30 minutes through streamlining in-hospital work-up. 10, 11 Successful strategies include pre-hospital notification, a ''code stroke'' system and rapid triage to the CT scanner. However, in consequence of long pre-hospital delays (mean 106 and 79 minutes), respectively, onsetto-needle times remained relatively long (mean 133 and 108 minutes). This observation makes clear that optimal reduction in treatment delay can only be achieved by streamlining all steps of the stroke rescue chain. It starts with public campaigns to improve awareness of stroke symptoms and the need of seeking immediate medical help. Although strong evidence of the effectiveness of such programs is equivocal, 12, 13 the increasing thrombolysis rates in many countries suggest that more patients are arriving to hospitals within the thrombolysis time window.
Pre-hospital notification of hospital-based stroke teams by the Emergency Medical System (EMS) crews accelerates the start of specific stroke treatments after hospital arrival. 14 As recognition of stroke patients is crucial for rapid processing, several stroke identification instruments have been developed and validated over the last years. They are either used at dispatch centers to prioritize rapid response or by EMS personnel in the field to pre-notify the receiving in-hospital stroke teams.
With the limited sensitivity and positive predictive value of the aforementioned stroke scores, 15 several initiatives have started to use telemedicine for telestroke assessment in ambulances. Broadband mobile communication technology according to the fourth generation (4G) or long term evolution (LTE) standard seems to overcome bandwidth restrictions and insufficient stability of video examination. 16 The most recent approach to achieving faster stroke treatment is by equipping and utilizing specialized ambulances with imaging and lab capability and staff trained in stroke recognition and treatment-MSUs. 17 thrombolysis or improved triage. Hitherto, there is a lack of evidence concerning improved functional outcomes. However, there are some hints to why this is a reasonable expectation. The first randomized trial showed that prehospital management achieved a median symptom onset-to-therapy decision time of 56 min and a median symptom onset-to-treatment time of 72 min, without impaired safety. 18 The number of patients with time to therapy decision (end of all diagnostic work up) in the first ''golden hour'' from stroke symptom onset or time last seen normal significantly increased from 4% to 57%. 18 The Berlin Stroke Emergency Mobile (STEMO) led to a 10-fold increase of the rate of golden hour thrombolysis compared to regular care. 19 Golden hour thrombolysis is associated with higher frequency of discharge home rather than to a nursing facility or other institutions 20 and overall better outcome at discharge. 21 Reassuringly, the high rate of golden hour thrombolysis with MSU implementation seems to be reproducible in prehospital settings outside of Germany. 22 A registry-based comparison of patients receiving iv-tPA in a university hospital of Berlin or on STEMO revealed non-significant difference (OR 1.40, 95% CI 1.00-1.97; p ¼ 0.052) in favor of prehospital thrombolysis in terms of excellent functional outcome (mRS 1) after STEMO care. 23 With reduced times to treatment, secondary endpoints such as 3-month survival without severe disability were also better in the prehospital treatment group. 23 Reduction of time to thrombolysis is the essence of MSUs, but the effects of specialized stroke ambulances may not be restricted to this. Prehospital imaging and assessment by a neurovascular specialist lead to tailored triage putting patients on the right track at the earliest timepoint. 24 This may also be helpful in patients with head trauma. 25 Further benefits of MSUs have included a significant reduction in the rate of stroke patient admissions to hospitals without a dedicated stroke unit and similarly patients with ICH were more often admitted to hospitals with departments of neurosurgery. 26 The Cleveland group showed that endovascularly-treated patients had reduced process times after field triage in an MSU compared to historical controls. 27 
Active PRESTO groups
The group at the Hospital of the Saarland University, Germany first proposed 17 and realized 28 the MSU concept enabling prehospital diagnosis and treatment of stroke and diagnosis-based triage adhering to stroke guidelines and strict EMS legislations. A significant time gain associated with use of this concept was demonstrated. More recent studies are related to further technical innovations and relevance in different health care settings.
The STEMO group in Berlin, Germany studied prehospital stroke care in a large study population in an urban environment. 19 After assessing feasibility and safety, 29 they showed a major time gain in stroke management, an increase in treatment rates, and suggestion of better 90-day functional outcome. 23 Now, they plan city-wide coverage with several ambulances in close collaboration with the centralized ambulance service of the Berlin Fire Brigade.
The group in Houston, Texas, was the first to implement a MSU in the US and showed feasibility in this different health care system. 30 They tested technical solutions such a telemedicine 31 and demonstrated radiation safety. 32 They set up a large multicentric randomized trial (BEST-MSU study), which is expected to answer relevant questions regarding clinical benefit and cost effectiveness. 22 The group at Cleveland, OH, USA showed that treatment of acute stroke is feasible in physical absence of a physician on-board, but relying on paramedics and technicians with guidance entirely by remote physician via telemedicine. 27, 33 The group at Oslo are investigating the use of a MSU by anaesthesiologists, and propose the transfer of this MSU concept to helicopters that are-due to the specific geography-a key means of EMS in Norway.
The group in Memphis, Tennessee, USA, is using a high resolution scanner that allows improved imaging of head and neck vessels and the aortic arch. As experts in ultrasound and sonothrombolysis they also aim to apply these diagnostic and therapeutic options in the MSU.
Other active MSU programs include the Colorado University Hospital in Aurora, New York Presbyterian Hospital system, Mercy Hospital in Toledo Ohio, Rush Hospital and Northwestern Hospital in Chicago, Capital Health in Trenton, New Jersey, and University of Alberta program in Edmonton, Alberta, Canada. Additional programs are scheduled to start during 2017 in Paris France, Melbourne Australia, Los Angeles California, and likely other locations.
However, lacking to date are any truly randomized data which would minimize bias in assessing the true clinical benefit of earlier treatment on an MSU, or any prospective cost-effectiveness data.
Evidence for cost-effectiveness
Establishing MSUs is a complex task and requires investment. 30 The two available cost-effectiveness studies, however, both suggested that the financial expenditure pays off in the long run. 34, 35 There is an ongoing International Journal of Stroke, 12 (9) debate regarding the optimal setting for MSUs (e.g. rural vs. urban). For metropolitan settings, at least, time benefits justifying specialized ambulances up to average travel times of 18 minutes have been shown. 36 All cost-effectiveness analyses of MSUs so far have had to rely on modeled assumptions of achieved functional outcomes and cost incurred for long-term care. Future research will provide real time data and determine costeffectiveness more accurately. 22 There are several models of MSUs, and choice/ design will depend on local driving conditions, governmental regulations, clinical objectives, as well as economic and other concerns. Fully building out and equipping a MSU will cost somewhere between 600,000 and 2 Million USD.
MSU staff requires at least two medically-trained individuals to deliver on-scene bedside care to the patient. This may be any combination of trained paramedic, registered nurse/nurse practitioner/advanced practice nurse, or physician. Also required is a radiology technologist trained in CT scanning. Having this person cross trained as a medic may help reduce costs. One person must be available to drive the vehicle. While the first prehospital thrombolysis projects relied on physician-staffed ambulances, telemedicine should help reduce costs of staffing MSUs.
Prehospital triage of patients for endovascular treatment
Endovascular thrombectomy dramatically reduces the risk of long-term disability in acute ischemic stroke patients with large vessel occlusion (LVO). 37 However, prehospital patient triage in the era of ET represents a major challenge. Ideally, all acute ischemic stroke patients with LVO should be directly sent to the nearest stroke center with neuro-interventional facilities, because, as with tPA, the benefit of ET is highly time-dependent. 38 Conversely, ischemic stroke patients unlikely to have an LVO should be referred to the nearest stroke center, hence avoiding overwhelming ET-capable stroke centers and supporting adequate stroke therapy in shortest distance to patients' homes. However, despite the development of several dedicated clinical scores, it remains very difficult to predict LVO in the prehospital setting. [39] [40] [41] Indeed, using published cutoffs for triage, such clinical scores may potentially miss around 20% of LVO, which could result in a loss of opportunity for these patients who would be inappropriately sent to a center lacking ET capability. 15, 42, 43 Conversely, using cutoffs reducing the falsenegative rate of LVO detection to 10% would result in sending almost every patient with acute neurological symptoms to a ET capable stroke center. 42 Of note, no (non-imaging) biological marker, alone or in combination with clinical parameters, has been shown to be specific for LVO prediction.
By bringing imaging to the prehospital field, MSUs represent an important opportunity to improve patient triage to centres offering ET. 24, 26, 27 Indeed, noncontrast brain CT scan can immediately rule out hemorrhagic stroke and can help differentiate ischemic stroke from stroke mimics, whereas intracranial CT angiography (CTA) provides prehospital information about absence or presence of LVO. 24 Telemedicine allows neuro-interventionists to access the CT/CTA images and to determine whether ET is indicated, in which case the patient can be directly transported to the cath lab of the nearest ET-capable stroke center, with pre-notification of the endovascular team. 27 
MSU models in different environments
Mobile stroke units have great potential in both urban and rural settings. The exact application of MSUs in a particular setting will depend upon many factors, including but not limited to population density, geography, climate, local EMS protocols, and hospital relationships.
To date, most MSUs have been developed in urban settings. 17, 19, 27, 30 These generally operate with codispatch of both standard EMS and the MSU if the dispatcher through their algorithm identifies a situation of a possible stroke. EMS teams typically arrive first, due to many units being distributed around the city, and will assess the patient utilizing a pre-hospital scale. Once arriving on scene, if stroke is suspected, the MSU team assumes care of the patient for assessment and management. Following initial management, including tPA if indicated, a decision regarding triage and drop-off destination will be made. Many urban environments have multiple hospitals and hospital systems, having different capabilities in caring for stroke patients (i.e. comprehensive vs. primary stroke centers, ET-capable centers, neurosurgery capable hospitals). Before launching a MSU program, triage algorithms should be established taking into consideration diagnosis of the patient, severity, patient preference and possibly other factors depending on region, laws and regulations.
The MSU model can also be applied to the rural setting. The University of Saarland program operates in the city of Homburg and also services the surrounding countryside of the Saarland. 17 Though the population density is less than a dense metropolitan area, significant reductions in time to decision can be made. Stroke severity is a major determinant for triage, allowing severe patients to be transported to the major university center, while less severely affected patients can remain at their local hospital. The program at the University of Alberta will cover a large rural region, utilizing a rendez-vous International Journal of Stroke, 12(9) model. The MSU will travel out to meet the incoming ambulance and initiate treatment, which should result in significant time savings. This rendezvous approach has also been applied to urban areas close to the periphery of the MSUs direct response area, effectively increasing the service areas of these units. 22 The majority of MSUs presently utilize physician presence on board the MSU to deliver care. However, it is also feasible to have virtual presence of the neurovascular specialist via telemedicine. 31, 33 As the MSU concept continues to develop in various environments, the use of telemedicine will likely be an important factor when considering its cost-effectiveness and widespread application.
Mobile stroke unit staffing
Different staffing models support each MSU program and are based largely on manpower availability, radiation safety requirements, role capabilities, and prehospital care regulations. While regulations vary in different countries and even within individual states, most require that vehicles classified as ambulances be staffed with individuals educated and credentialed to work in prehospital emergency settings, such as emergency medical technicians (EMTs) and EMT-paramedics (EMT-P). 44, 45 Additionally, drivers of vehicles classified as ambulances must hold special drivers' licenses earned after training and testing for high speed emergency transport. 44 Because of the highly specialized nature of MSU work, additional staff must supplement the required EMT/EMT-P crew. First and foremost is the need for vascular neurology expertise. While this role could be filled by vascular neurologists themselves and/or those currently completing vascular neurology fellowship training, the limited supply of vascular neurologists within some countries, including the US, makes this unfeasible for many centers. Alternatives to use of vascular neurologists in the field commonly include telemedicine-based physicians supported by a registered nurse crew member who is experienced in emergency assessment and management of acute stroke patients. However, no countries permit a licensed registered nurse without nurse practitioner (NP) licensure and credentialing to independently order medications and testing, and non-NPs may not take orders from EMT or EMT-P crew members, and are therefore subject solely to the direction provided by licensed physicians or NPs. [46] [47] [48] [49] The Memphis MSU is staffed by vascular neurology board certified NPs 50 who work similarly to on-board vascular neurologists, localizing clinical findings, reviewing the CT and CTA source images, and providing acute treatments including tPA, supported by telephone availability of physician consultation. All staffing configurations must be supported by a strict quality improvement process including case review to ensure both accurate diagnostic performance and safe practice.
While standards likely vary by country, safe management of CT imaging in the MSU requires staffing a CT technologist. In the USA, most states require licensing of CT technologists. Radiology technologists first complete either an associate's or a bachelor's of health science degree which makes them eligible for registration with The American Registry of Radiologic Technologists; the RT credential is then supplemented with additional education and training for registration as a CT technologist. 51 Many CT technologists are also cross trained and skilled in other forms of imaging such as transcranial Doppler and duplex imaging, and in obtaining intravenous access.
An overall consideration for MSU staff is the need to understand roles and direction based on the expertise that each of these skilled providers brings to the scene. For example, EMTs and EMT-Ps are experts at prehospital scene management, and therefore the scene should be secured and overseen by these providers. Additionally, because prehospital care may often include medical events beyond that of an initial stroke presentation (including extreme events such as respiratory and/or cardiac arrest), EMTs and EMT-Ps bring substantial expertise to the management of these nonstroke emergencies that should be respected. Local government sanctioned ambulances staffed with EMTs and EMT-Ps are also supported by district, regional, or state protocols that direct how to manage a wide variety of emergencies beyond stroke. Therefore, when the MSU is integrated into the regional EMS system, it should adopt these protocols thereby preventing the need to write extensive new protocols across numerous disease states.
Finally, experts on board the MSU must establish comfortable collaborative working relationships with all prehospital care professionals to support optimal patient care. The prehospital care setting can be chaotic and unpredictable, including everything from unsafe locations, to highly erratic behavior on scene. 52 Combined with unstable patient circumstances, the prehospital environment may challenge the performance of even the best clinicians. All these considerations mandate that potential providers should be cautiously vetted for appropriate fit for roles on an MSU.
Planned PRESTO research collaborations Evidence for MSUs as valuable research platforms
MSUs have proven to be a valuable research platform. The usefulness of several biomarkers has been investigated from prehospital blood samples drawn in a specialized stroke ambulance. 53, 54 New imaging software has also been tested in these ambulances. 55 Dedicated teams, specialized in stroke care and with a strong research background will make the best use of MSUs for further research.
MSUs offer additional potentials to improve functional outcomes such as by prehospital reversal of oral anticoagulation or ultra-early blood pressure lowering in cases of ICH. 17, 56 But ultimate proof of improved outcome in patients treated in MSUs is still lacking. PRESTO is determined to close this important knowledge gap in the near future.
Several research collaborations were envisioned during the first PRESTO meetings. The following PRESTO-wide initiatives were suggested by the Steering Committee or members, and then agreed upon by unanimous vote of attendees based on their perception of feasibility, impact and fundability.
1. The researchers of the four ongoing or planned controlled trials plan to merge their data to increase statistical power and allow for further analyses.
Minimal data sets will be agreed including joint definitions of functional outcomes (see Appendix 1, which is available online, http://journals.sagepub. com/doi/full/10.1177/1747493017729268). 2. In addition, the entire PRESTO group intends to enter all stroke patients in a joint registry using this minimal data set. 3. At least two prehospital studies on diagnosis and treatment of ICH are planned to investigate the ultra-early dynamics of hematoma expansion and the effects of prehospital blood pressure control and reversal of oral anticoagulation. 4. The PRESTO partners will consider joint studies on biomarkers in hyperacute stroke. These studies will both investigate the accuracy of known biomarkers (such as glial fibrillary acidic protein) and search for new biomarkers that can help to identify stroke mimics or differentiate ischemic and hemorrhagic strokes. 5. Finally, the PRESTO members will collaborate in future industry-sponsored studies by acting as a collaborative research group.
Planned PRESTO organizational activities
Research
In addition to research already identified above, broader scale research is already underway or envisioned orchestrated by individual PRESTO sites. For instance, the ''BEnefits of Stroke Treatment Using a Mobile Stroke Unit Compared to Standard Management (BEST-MSU)'' study is a prospective multi-centered cluster randomized (by weeks) comparative effectiveness study investigating outcomes and cost/benefits of MSU implementation compared to Standard Management in the US. This study is designed to minimize bias by enrolling patients as similarly as possible on MSU vs. control weeks, and adjudicating all patients' study eligibility by an independent investigator blinded to MSU vs. control group assignment. All patients will be followed for a full year to gather data on resource utilization and costs. Finally, outcomes are patient-centered including quality of life, and modified Rankin score weighted by utility scores derived from actual patient preferences. 57 Enrollment of over 900 tPA-eligible patients is planned with over 350 enrolled to date (www.ClinicalTrials.gov NCT02190500). The study is expected to take 4-5 years to complete including 1 year follow-up of all patients. The ''Berlin-Prehospital Or Usual Care Delivery (B_PROUD)'' study in Germany is a prospective quasi-randomized study (allocation according to availability of the Berlin STEMOs) that will include all patients who have focal neurological symptoms at arrival of first EMS vessel, a final diagnosis of ischemic stroke or TIA and no contra-indication to either thrombolysis or ET. These selection criteria will avoid bias of different stroke severity scores in both arms as a consequence of differing assessment times. Enrollment of approximately 1500 treatment candidates is planned over a 2-3 years period including 3 months blinded follow-up assessment (www.ClinicalTrials.gov NCT02869386).
The ''Acute Stroke: Prehospital versus in-HospitAL initiation of recanalization Therapy'' (ASPHALT) study will be a randomized controlled trial of MSU deployment versus standard care, aiming to assess the cost-utility of an MSU for stroke management in the era of bridging therapy. Randomization will be performed on an individual patient basis. Two geographic areas in France will be involved. 450 acute ischemic stroke patients will be recruited over a 3-year period expected to start in 2017, with a blinded follow-up of one year.
A German study on use of MSUs in a rural region (''Mobile Stroke Unit-Concept for Delivery of Specialized Acute Stroke Care to Patients in Remote Areas'') aims to provide further evidence on the use in such a setting, which requires further definition. The study will be week-wise randomized and include 250 patients (www.ClinicalTrials.gov NCT02465346). Grants for funding are submitted.
While the described studies are not run under the umbrella of PRESTO, PRESTO endorses the studies, and PRESTO members are invited to submit collaborative research ideas to study leaderships. A pooled International Journal of Stroke, 12 (9) analysis of the studies is planned in order to increase statistical power and enable subgroup analyses.
It is hoped that emanating from the ICH studies already described, PRESTO will help organize an international collaborative study using PRESTO member MSUs as a platform to test ultra-early interventional treatment in ICH patients. As an example, there is interest in a collaborative trial of hemostatic therapy with tranexamic acid, to attenuate hematoma growth.
Meetings
The PRESTO satellite meetings at the annual International Stroke Conference (ISC) and European Stroke Congress (ESOC) will be chaired and organized by the PRESTO co-chairs and Steering Committee, with help from local PRESTO members, and having a program comprised of PRESTO members. Apart from conference meetings, further symposia are organized by different working groups (e.g. 2012 in Oslo Norway, 2014 in Brooklyn NY, 2016 in Cleveland Ohio).
Attendance will be open. Industry will be invited to exhibit, with exhibitor fees used to support meeting costs. The first component will be to inform on PRESTO activities; this will include (1) PRESTO organizational activities, (2) the state of MSU development worldwide, and (3) the state of ongoing research at PRESTO centers. PRESTO members are expected to submit and present their research at the ISC and ESOC meetings and not at the PRESTO meeting. Only a brief summary of ongoing research will be presented at the PRESTO meetings.
The second component will be 2-3 plenary lectures by PRESTO members describing activities promoting the PRESTO mission of research and advocacy. This may include further in-depth presentation and discussion of important research results presented at the parent ISC or ESOC meeting that are relevant to prehospital MSU-based stroke treatment.
Other advocacy PRESTO will be the primary spokes-group for MSUbased pre-hospital stroke treatment. Therefore, it may be a resource for public education, helping other organizations such as the American Heart Association, European Stroke Organization or World Stroke Organization in providing material and data for educating the public on stroke symptoms and signs and encouraging activation of Emergency Medical Services. PRESTO will also help those members embarking on MSU programs to advocate local and regional government for appropriate legislation and licensing to facilitate MSU implementation. PRESTO will also approach government and private insurers to advocate for appropriate reimbursement to support MSU-based pre-hospital stroke management. Finally, PRESTO will be a clearing house to help generate support from industry stakeholders such as ambulance manufacturers, imaging companies, and telemedicine and stimulus for government, industry, and philanthropic support.
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